Clinical Trials Logo

Paraganglioma clinical trials

View clinical trials related to Paraganglioma.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04276597 Withdrawn - Clinical trials for Neuroendocrine Tumors

Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.

PUTNET
Start date: March 4, 2020
Phase: Phase 2
Study type: Interventional

Determine the safety and effectiveness of Lu-177 DOTATOC in adult subjects with somatostatin receptor-expressing Pulmonary, Pheochromocytoma, Paraganglioma, Unknown primary, and Thymus neuroendocrine tumors or any other non-.GEP-NET. The treatment regimen will consist of 4 doses of 200 (±10%) mCi 177Lu-DOTATOC administered at 8+/- 1-week intervals.

NCT ID: NCT04106843 Withdrawn - Clinical trials for Metastatic Adrenal Gland Pheochromocytoma

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

Start date: June 13, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well 177Lu-DOTATATE works in treating patients with rare endocrine cancers that have spread from where they started to nearby tissue or lymph nodes (locally advanced), spread to other places in the body (metastatic), or cannot be removed by surgery (unresectable). Radioactive drugs, such as 177Lu-DOTATATE, may carry radiation directly to cancer cells and not harm normal cells. 177Lu-DOTATATE may help to control endocrine cancers compared to standard treatment.

NCT ID: NCT03923257 Withdrawn - Clinical trials for Neuroendocrine Tumors

Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents

Start date: August 4, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase I/II peptide receptor radiotherapy (PRRT) trial of 177Lu-DOTA-OCTREOTATE in children and adolescents with neuroendocrine tumors and pheochromocytoma or paraganglioma.

NCT ID: NCT01941849 Withdrawn - Paraganglioma Clinical Trials

Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma

VIBRaNT
Start date: October 2014
Phase: Phase 1
Study type: Interventional

The phase I trial aims to determine the recommended phase II dose (RP2D) of vandetanib in combination with standard radiation therapy, 131I-mIBG, in patients with advanced phaeochromocytoma (phaeo) and paraganglioma (PG) by assessing the safety and tolerability of the combination treatment.